Adenium Biotech

Name

Adenium Biotech

Legal name

Adenium Biotech

Website

https://adeniumbiotech.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Digital Commerce or Content

Cost components

Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Amazon Associate Affiliate Commissions: The company earns commissions from qualifying purchases made through Amazon affiliate links embedded in product reviews and recommendations. The site participates in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide fees for advertising and linking to Amazon.com.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Adenium Biotech operates a consumer-facing product review blog at adeniumbiotech.com that publishes hands-on reviews, buying guides, side-by-side comparisons, and personal recommendations across categories including supplements, kitchen products, sports equipment, beauty/skincare, and outdoor gear. The site monetizes exclusively through the Amazon Services LLC Associates Program, earning commissions on qualifying purchases made via embedded affiliate links within the editorial content.

Product overview

Adenium Biotech (adeniumbiotech.com) is a product review blog operated by Gayle Burges that publishes hands-on reviews, buying guides, and personal recommendations across diverse consumer product categories including supplements, health foods, sports equipment, and kitchen goods. The site does not offer its own proprietary products or services; rather, it curates and evaluates third-party products (primarily available on Amazon) and publishes affiliate-supported editorial content.

Differentiator

Problem solved

Functional benefit

Products and services

• Adenium Biotech Product Review Blog A free, content-driven review platform targeting individual consumers seeking honest, hands-on product evaluations across categories such as supplements, kitchen goods, sports equipment, and beauty products. The blog is monetized through embedded Amazon Associates affiliate links rather than through subscription or direct sales.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Amazon.comcoreChannel Partner/ Reseller/ DistributorAdenium Biotech is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program. The company earns advertising fees by advertising and linking to Amazon.com products. The Amazon, Amazon logo, Amazon Supply, and Amazon Supply logo are trademarks of Amazon.com, Inc.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Nabriva Therapeutics: Biopharma developing lefamulin and earlier-stage antibacterial agents for community-acquired and resistant infections; comparable as a small, single-indication-focused antibiotic developer.
• Melinta Therapeutics: US small-cap antibiotic developer commercializing and developing agents against resistant pathogens; directly comparable to Adenium as a small, focused antibacterial biopharma pursuing FDA pathways.
• Paratek Pharmaceuticals: Antibiotic-focused pharmaceutical company developing tetracycline-class therapeutics for resistant infections; comparable business model, single-asset concentration, and AMR-focused value proposition.
• Iterum Therapeutics: Clinical-stage anti-infectives company developing sulopenem for resistant Gram-negative and uncomplicated urinary tract infections; directly comparable as a small antibiotic-focused biopharma targeting AMR.
• Tetraphase Biosciences: Small pure-play antibiotic biotech developing eravacycline against multidrug-resistant pathogens; peers Adenium as a focused antibacterial developer of similar size and clinical-stage profile.
• Spero Therapeutics: Clinical-stage antibacterial biopharma focused on novel mechanisms (tebipenem, SPR206) for MDR Gram-negative and rare disease infections; directly overlaps Adenium's AMR-focused, single-modality R&D model.

Broad incumbents

• Lundbeck: Established Danish CNS-focused pharmaceutical company with global commercial infrastructure; relevant as the dominant Danish biopharma acquirer/partner that an exit pathway for Adenium would likely flow through.

Regional players

• Genmab: Copenhagen-headquartered clinical-stage biotech developing antibody therapeutics; comparable as a Danish small-cap biopharma with similar origin in Danish life-science ecosystem and Novo/Novo-Nordisk-adjacent investor base.
• Zealand Pharma: Copenhagen-based clinical-stage peptide-therapeutics biotech; comparable as a Danish small-cap biopharma with shared Nordic biotech investor base and similar early-stage capital profile.
• Bavarian Nordic: Danish-listed vaccine and immuno-oncology biopharma; relevant Danish counterpart for benchmarking capital structure, governance and Nordic investor dynamics even though therapeutic area differs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/adenium-biotech-aps

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adenium Biotech